A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of
entospletinib (GS-9973) in combination with vincristine (VCR), and dexamethasone in adults
with previously treated relapsed or refractory B-cell lineage acute lymphoid leukemia (ALL).
This study consists of two parts: Dose Escalation and Dose Expansion. After 2 induction
cycles during either parts of the study, participants may be put on maintenance for up to 36
cycles if they have obtained clinical benefit from the treatment.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society